Opus Genetics, Inc.
OPGx-LCA5
Leber Congenital Amaurosis (LCA5)
Resolved
37days ago
Phase 1 readout · ~ May 31, 2026 estimated
What's at stake
Phase 1 trial results for OPGx-LCA5 in Leber Congenital Amaurosis (LCA5) are due ~ May 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Presentation of Phase 1/2 six-month pediatric cohort data expected at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) conference in May 2026.”